GlassScriptPhysician profile
Heather G Talbot
NPI 1922034354
$1,779.40
in general payments reported to CMS, 2019-2025
23 companies · $406 in 2025
The $406 reported for 2025 was more than what 77% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $160 · 2022: $476 · 2023: $356 · 2024: $380 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,142.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $467.98 | 2022-2025 | |
| Abbvie INC. | $302.99 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $120.79 | 2023-2024 | Myfembree |
| Exact Sciences Corporation | $118.92 | 2025 | The Cologuard Plus Collection Kit |
| Biogen, INC. | $113.47 | 2025 | Zurzuvae |
| Therapeuticsmd, INC. | $88.73 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $84.87 | 2021-2024 | |
| Pfizer INC. | $81.23 | 2022-2023 | |
| Axsome Therapeutics, INC. | $50.84 | 2023-2024 | Auvelity |
| Myovant Sciences INC. | $44.38 | 2021-2022 | |
| Mission Pharmacal Company | $34.21 | 2022-2024 | Uribel Tabs |
| Mylan Pharmaceuticals INC. | $33.60 | 2022 | |
| Organon LLC | $33.44 | 2022-2023 | Nexplanon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.50 | 2023-2024 | Xifaxan, Trulance |
| Currax Pharmaceuticals LLC | $27.78 | 2022-2023 | Contrave |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascend Therapeutics US, LLC | $23.59 | 2023 | |
| Medtronic, INC. | $22.98 | 2022 | |
| Astellas Pharma US INC | $22.76 | 2023 | Myrbetriq |
| Axonics, INC. | $22.14 | 2023 | Bulkamid |
| Mycovia Pharmaceuticals, INC. | $21.17 | 2023 | Vivjoa |
| Agile Therapeutics, INC. | $15.01 | 2022 | |
| Channel Medsystems, INC. | $10.70 | 2024 | |
| Evofem Biosciences, INC. | $9.32 | 2025 | Solosec, Phexx, Phexxi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Talbot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.